BioNTech’s $622 Million Quarter Sets the Stage for a Pumitamig Reckoning at ASCO

The cost of BioNTech’s transformation is no longer theoretical. In the first quarter alone, the company burned through $651.6 million in research and development spending while its net loss ballooned to $622.3 million. Revenue from the fading Covid-19 vaccine franchise fell to $138 million, down from $213.8 million a year earlier. The numbers paint a clear picture: BioNTech is spending heavily to pivot toward oncology, and the market has taken notice. The stock, trading at €76.05 in Frankfurt, has lost 15.45% over the past month and sits perilously close to its 52-week low of €72.50.

To manage the financial strain while preserving its strategic runway, BioNTech has a formidable cushion: $19.6 billion in cash and equivalents. The company also secured a $1 billion share buyback authorization in May, valid for 12 months (until May 6, 2027), though timing and volume depend on market conditions. More structurally, BioNTech is slimming down its manufacturing footprint. Pfizer will take over full production of their jointly marketed Covid-19 vaccine by year-end, freeing up capacity. Meanwhile, the company plans to close three German production sites — Idar-Oberstein, Marburg and Tübingen — affecting roughly 1,860 positions. Management expects these measures to generate annual savings of up to €500 million from 2029 onward, savings that will be redirected into the oncology pipeline.

That pipeline now stands as the ultimate arbiter of BioNTech’s post-Covid strategy. The company is targeting 15 phase 3 trials by the end of 2026, with seven late-stage data readouts coming this year alone. Already more than 25 advanced studies are running across 17 clinical programs. Key assets include the anti-CTLA-4 antibody gotistobart, the HER2-directed antibody-drug conjugate BNT323, and the bispecific BNT327. But no candidate carries more weight at this moment than Pumitamig, a bispecific immunomodulator that combines PD-L1 checkpoint inhibition with VEGF-A neutralization, developed in partnership with Bristol Myers Squibb.

Should investors sell immediately? Or is it worth buying BioNTech?

Pumitamig’s acid test arrives at this year’s American Society of Clinical Oncology (ASCO) annual meeting, which runs from May 29 to June 2 in Chicago. The abstract embargo lifts on Thursday evening U.S. time, giving doctors and investors their first detailed look at data from the ROSETTA-Lung-02 study. This phase 2 trial tests Pumitamig plus chemotherapy against the standard of care — Merck & Co.’s Keytruda (pembrolizumab) plus chemotherapy — in first-line non-small cell lung cancer. Phase 3 enrollment is already underway, and a positive readout would not only boost Pumitamig’s prospects but also validate the broader oncology narrative that BioNTech has staked its future on.

The clinical stakes are matched by the financial ones. For the full year, BioNTech maintains revenue guidance of $2.3 billion to $2.6 billion, but the swing factor is no longer vaccine sales — it is how quickly the pipeline can deliver. The company’s board has strengthened its bench accordingly, adding two new members with deep clinical and oncology expertise at the recent annual general meeting, where all agenda items passed with strong shareholder support. Yet the stock remains technically weak: the share price sits well below its long-term moving average, and the relative strength index suggests no extreme oversold conditions. Investors are waiting for hard data, not strategic pronouncements.

One oncologist described Pumitamig’s mechanism as “exciting” from both a mechanistic and class perspective ahead of the data release. If the ROSETTA-Lung-02 results show a convincing signal, it would provide the strongest support yet for BioNTech’s claim that it can become a multiproduct oncology company. If they disappoint, the high cost of the transformation — the factory closures, the R&D burn, the flat cash pile that must last through multiple approvals — will become far harder to defend. For BioNTech, ASCO is not just a conference. It is the first major proving ground of its post-pandemic identity.

Ad

BioNTech Stock: New Analysis - 20 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH’S | boerse | 69381380 |